Excipient Supplier Risk Classification & Quality Audit Strategy
Introducing how pharmaceutical manufacturers classify excipient suppliers based on use (sterile, oral, topical), supplier systems, and raw material risk.
Drug manufacturers must classify excipient suppliers per QRM principles (ICH Q9). Classification parameters include: excipient intended use (sterile formulations belong to critical risk; oral solids are moderate); excipient source (animal-derived excipients pose TSE/BSE risk, classified as high); and supplier QMS status (EXCiPACT certified vs. uncertified). Results define whether site audits, paper audits, or simple document checks are executed.
Audit Types & Frequencies Based on Risk Levels
Quality departments must distribute audit resources based on classification matrices, establishing a clean Approved Material List (AML).
- Critical/High risk (sterile formulation or animal excipients): site audits every 2-3 years mandatory, paper assessments not allowed
- Medium risk (standard oral solid binders): if valid EXCiPACT exists, site audit intervals can extend to 4-5 years or use paper audits
- Low risk (basic inorganic packaging mineral, standard colorants): initial document checks and annual COA data cross-checks
FAQ
What is TSE/BSE risk and how do suppliers declare it?+
TSE/BSE is a critical biological risk for animal-derived excipients (gelatin, magnesium stearate). Suppliers must issue a TSE/BSE Free Declaration detailing animal sources, country of origin, and processing certificates complying with Ph. Eur. 5.2.8.
Next steps
If this topic applies to your product, facility, or supply chain requirement, start by confirming the target market, customer-required standard, existing documents, audit history, and expected timeline.
